Astra Zeneca
AstraZeneca PLC, a leading global biopharmaceutical company, is headquartered in Cambridge, GB. Founded in 1999 through the merger of Astra AB and Zeneca Group PLC, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in the research, development, and manufacturing of innovative medicines, AstraZeneca focuses on areas such as oncology, cardiovascular, renal, and respiratory diseases. With a commitment to advancing healthcare, AstraZeneca is renowned for its unique portfolio of products, including groundbreaking therapies like Tagrisso and Imfinzi. The company has achieved significant milestones, including rapid vaccine development during the COVID-19 pandemic, solidifying its position as a market leader in the pharmaceutical industry. AstraZeneca continues to drive innovation, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Astra Zeneca's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astra Zeneca's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astra Zeneca's reported carbon emissions
In 2023, AstraZeneca reported total greenhouse gas emissions of approximately 5,917,160,000 kg CO2e, with emissions distributed across various scopes: 180,898,000 kg CO2e from Scope 1, 19,940,000 kg CO2e from Scope 2, and 5,916,716,000 kg CO2e from Scope 3. The company has set ambitious climate commitments, aiming for a 98% reduction in absolute Scope 1 and 2 emissions by 2026, using 2015 as the baseline year. Additionally, AstraZeneca targets a 50% reduction in absolute Scope 3 emissions by 2030, with a 90% reduction goal by 2045, both from a 2019 baseline. AstraZeneca's initiatives include specific targets for various categories within Scope 3 emissions, such as an 80% reduction in emissions from fuel and energy-related activities, upstream leased assets, and downstream leased assets by 2030. The company also aims for a 95% reduction in emissions from the use of sold products and a 46% reduction in emissions from upstream transportation and distribution, waste generated in operations, business travel, employee commuting, and end-of-life treatment of sold products. Furthermore, AstraZeneca is committed to ensuring that 95% of its suppliers by spend for purchased goods and services and capital goods, and 50% of its suppliers for upstream transportation and distribution and business travel, will have science-based targets by 2025. These commitments align with the company's overarching goal of achieving net-zero greenhouse gas emissions across its value chain by 2045.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astra Zeneca is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
